Friday, December 20, 2013 4:10:23 AM
1. Substantial legacy debts
2. Difficult to scale up without new capital
3. At least three former management teams
4. The most recent former CEO walked out in the middle of a strategic license negotiation for our probiotics startup
5. Our old software must be brought up-to-date in an economical and useful way, which requires cost-effective access to talent
6. Our new software must be developed beyond stage 1 functionality in an economical and useful way that gives us a competitive advantage and products that appeal to customers
7. Our shares are not registered under the 1934 Exchange Act so the regulatory compliance issues are more complicated than usual
8. The SEC is actively conducting an informal investigation into Public Startup Company, Inc. which is strategically-important to our future growth, so if the SEC decides to take enforcement action for some reason it could disrupt our current plan of execution which has been in process since 2007
9. Marketing is especially challenging for us at this time, while still working on changing our corporate name and trying to source capital for advertising campaigns, plus forming new relationships with startup co-founders, co-developers and clients who can see the potential here and need our expertise, products and services
10. As summarized in my previous Letters to Stakeholders, without new capital we are limited, for practical reasons, to being a professional services consulting firm with a business model similar to that of a law firm, which is certainly a viable business but not one that is easy to scale particularly when starting from an encumbered starting point as we are.
5. Our old software must be brought up-to-date in an economical and useful way, which requires cost-effective access to talent
Cost effective access to talent --- meaning?
Recent ADIA News
- Adia Med Now Recruiting for Kidney Health and Lower Back Pain Studies Listed on ClinicalTrials.gov • Newsfile • 05/20/2026 03:58:00 PM
- ADIA Nutrition, Inc. Reports Strong Revenue Growth and Operational Momentum for First Quarter 2026 • Newsfile • 05/15/2026 11:59:00 AM
- ADIA Nutrition Announces IRB Approval of All Four Clinical Studies and Registration of Kidney Health Study on ClinicalTrials.gov • Newsfile • 05/11/2026 02:04:00 PM
- Adia Nutrition Announces IRB Approval and ClinicalTrials.gov Submission for Groundbreaking Stem Cell Study in Chronic Kidney Disease (CKD) • Newsfile • 05/05/2026 02:08:00 PM
- Adia Nutrition Announces Three Pivotal Clinical Studies Receive Major IRB Milestone - Final Approval Now Clearly in Sight • Newsfile • 04/28/2026 12:30:00 PM
- Adia Nutrition, Inc. Announces Corporate Name Change to Adia Med, Inc. to Better Align with Its Regenerative Medicine and Biologics Business Model • Newsfile • 04/15/2026 12:30:00 PM
- Adia Nutrition Strikes Major Partnership with Leading Atlanta Clinic to Launch Groundbreaking Autism Clinical Study • Newsfile • 04/08/2026 12:30:00 PM
- Adia Nutrition, Inc. Reports Strong Revenue Growth in 2025 Annual Report, Highlighting Transition to Regenerative Medicine and Full SEC Reporting Status • Newsfile • 04/01/2026 02:07:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2026 07:49:04 PM
- Tonight: Adia Nutrition and UCF CARD Host Live Zoom on Revolutionary Stem Cell Study for Autism - Strong Interest Already Building • Newsfile • 03/24/2026 12:00:00 PM
- Adia Med of Winter Park Appoints Amy Dalrymple, APRN, Former Mrs. Florida United States, to Lead Regenerative Aesthetics Division • Newsfile • 03/17/2026 01:30:00 PM
- Adia Med Unveils a Fresh Facelift: New Website by ZenChange Marketing Spotlights Cutting-Edge Regenerative Medicine Studies • Newsfile • 03/09/2026 01:38:00 PM
- Adia Nutrition Announces Submission of Final Revised Protocol for Lower Back Pain Study with AdiaVita • Newsfile • 03/03/2026 03:20:00 PM
- Adia Med of Winter Park Expands into Cosmetics Due to High Patient Demand - Now Interviewing Nurse Practitioners for Hair Growth and Aesthetic Procedures • Newsfile • 02/24/2026 01:30:00 PM
- Adia Nutrition Announces Subsidiary Adia Med's Submission of Second Clinical Study for IRB Review Targeting Lower Back Pain with AdiaVita • Newsfile • 02/16/2026 02:00:00 PM
- Adia Nutrition Inc. Plans to Initiate Four to Five New Clinical Studies in 2026, Including Expansions in Autism and New Rheumatoid Arthritis Research • Newsfile • 02/09/2026 01:31:00 PM
- Adia Nutrition Inc. Announces Effectiveness of Form 10 Registration Statement - Now a Fully Reporting SEC Company and Advancing Toward Next Phase of Growth and NASDAQ Uplisting • Newsfile • 02/04/2026 02:32:00 PM
- Adia Nutrition Inc. Announces Dr. Brian Browning as Lead Physician for All Orthopedic Treatments and Specialties at Adia Med • Newsfile • 02/02/2026 02:00:00 PM
- Adia Nutrition Announces Documentary Featuring WWE/TNA Superstar Elias/Elijah Jeff Sciullo's Recovery with Adia Med's AdiaVita Stem Cell Treatment • Newsfile • 01/28/2026 03:00:00 PM
- Adia Nutrition Announces Every Child in Autism Stem Cell Study Receives Umbilical Cord Blood-Derived Stem Cell Treatments Three Times - Open Nationwide and Worldwide with Participation Cost • Newsfile • 01/26/2026 03:00:00 PM
- Adia Nutrition Inc. Receives Notification from SEC: Form 10 to Become Effective on February 3, 2026 • Newsfile • 01/20/2026 02:30:00 PM
- Adia Nutrition Promotes Emmanuela Derisbrun, APRN, FNP-C, to Provider Role Amid Growing Patient Demand and Launch of Autism IRB Study • Newsfile • 01/15/2026 04:03:00 PM
- Adia Med Kicks Off Recruitment Today for Innovative Autism Stem Cell Study • Newsfile • 01/13/2026 03:16:00 PM
- ADIA Nutrition Appoints Dawn Bell as Chief Revenue Officer to Accelerate Growth and Drive Success Across Physician Network • Newsfile • 01/08/2026 01:30:00 PM
- Adia Nutrition Inc. Announces Landmark Autism Spectrum Disorder Clinical Study Now Live on ClinicalTrials.gov • Newsfile • 01/05/2026 03:21:00 PM
